Search clinical trials for: Pegylated interferon-alfa-2b and ribavirin

Total 1157 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

Head and Neck Cancer

United States
Hoffmann-La Roche

Completed

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

Chronic Hepatitis C

Germany
BioWest Therapeutics Inc

Unknown

A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Chronic Hepatitis C

Canada
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Ortho Biotech Products, L.P.

Completed

NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection

Anemia | Hepatitis C | HIV
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
Hepatitis Resource Network
Integrated Therapeutics Group; Subsidiary of Schering-Plough

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

HIV Infections | Chronic Hepatitis C Infection in HIV-Infected Persons

United States
French National Agency for Research on AIDS and...
Schering-Plough

Terminated

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

Hepatitis C, Chronic

France
Hoffmann-La Roche

Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Hepatitis C, Chronic

Spain, United States, Germany, Canada, Austria, France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Bladder Cancer | Urethral Cancer

United States
Mayo Clinic
Unity Health Toronto; Augusta University; Schering-Plough

Terminated

Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

Anemia | Liver Disease | Hypoxemia

United States
Transgene

Completed

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients (HCVac)

Chronic Hepatitis C Infection

Germany
Merck Sharp & Dohme LLC

Terminated

Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Hepatitis C | Hepatitis C, Chronic
Queen Mary University of London
Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust; Janssen-Cilag... and other collaborators

Completed

Telaprevir in Genotype 3 HCV (TIG3)

Hepatitis C

United Kingdom
Hoffmann-La Roche

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

China
William Carson
Schering-Plough

Completed

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

Anemia | Hepatitis C
Mongolian National University of Medical Sciences
Mongolian National Cancer Center

Recruiting

Interferon Alpha Therapy for Cervical CINI and HPV Infection

HPV Infection | Cervical Dysplasia

Mongolia
Merck Sharp & Dohme LLC

Completed

Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)

Hepatitis C | Hepatitis C, Chronic
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Boceprevir on HCV-specific T Cell Responses (Boce-Par)

Chronic Hepatitis C

Italy
Merck Sharp & Dohme LLC

Completed

Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) (@dhere)

Hepatitis C | Chronic Hepatitis C
Australasian Leukaemia and Lymphoma Group
Merck Sharp & Dohme LLC; Novartis Pharmaceuticals

Unknown

Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe)

Chronic Myeloid Leukaemia

Australia
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Chronic Hepatitis C

Austria, France, Germany, United Kingdom
Luis Montaner
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Unknown

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

HIV/AIDS | HIV | HIV-1 Infection

United States
M.D. Anderson Cancer Center
Schering-Plough

Completed

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Melanoma

United States
Pacific Health Foundation
Hoffmann-La Roche

Completed

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

Chronic Hepatitis C | Treatment | Asian Americans | Novel Genotypes

United States
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Merck Sharp & Dohme LLC

Completed

PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)

Hepatitis B, Chronic (CHB)
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Merck Sharp & Dohme LLC

Terminated

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (RE-CHUT)

Hepatitis C | Hepatitis C, Chronic
Charles University, Czech Republic
IGA MZ, Czech Republic

Unknown

Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection

Nonalcoholic Steatohepatitis | Chronic HCV Infection

Czech Republic
Merck Sharp & Dohme LLC

Completed

Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C

United States
Merck Sharp & Dohme LLC

Terminated

Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Hepatitis C, Chronic
Cairo University
Egyptian Railway Hospital

Completed

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

Chronic Hepatitis c

Egypt
Merck Sharp & Dohme LLC

Withdrawn

Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

Chronic Genotype 1 Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Hepatitis C, Chronic
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
California Cancer Consortium
National Cancer Institute (NCI)

Terminated

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

The Clinical Cure Project of Chronic Hepatitis B in China

Hepatitis B, Chronic

China
PharmaEssentia

Completed

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

Chronic Hepatitis C Virus Infection

Korea, Republic of, Taiwan, China
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC

Terminated

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Myelofibrosis

United States
King Abdulaziz Medical City
King Faisal Specialist Hospital & Research Center; Riyadh Military Hospital

Completed

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Chronic Hepatitis C | Renal Transplant

Saudi Arabia
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) (PRACTICE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Hepatitis C | Hepatitis C, Chronic
ANRS, Emerging Infectious Diseases
Roche Pharma AG

Completed

ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV (ETOC)

Hepatitis

France

3

Subscribe